C. C. P. Aires

New insights on the mechanisms of valproate-induced hyperammonemia: Inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA

C. C. P. Aires, Arno van Cruchten, Lodewijk IJlst et al. · Journal of Hepatology · 2010 · 112 citations

Biochemistry, Valproate-induced Hyperammonemia, Medicine +9

Inhibition of hepatic carnitine palmitoyl-transferase I (CPT IA) by valproyl-CoA as a possible mechanism of valproate-induced steatosis

C. C. P. Aires, Lodewijk IJlst, Femke S. Stet et al. · Biochemical Pharmacology · 2009 · 85 citations · Full text

Hepatology, Biochemistry, Medicine +9

Valproic acid metabolites inhibit dihydrolipoyl dehydrogenase activity leading to impaired 2-oxoglutarate-driven oxidative phosphorylation

Paula B. Luis, Jos P.N. Ruiter, C. C. P. Aires et al. · Biochimica et Biophysica Acta (BBA) - Bioenergetics · 2007 · 54 citations

Dihydrolipoyl Dehydrogenase Activity, Oxysterol, Aldehyde Dehydrogenase +10

Pyruvate uptake is inhibited by valproic acid and metabolites in mitochondrial membranes

C. C. P. Aires, Graça Soveral, Paula B. Luis et al. · FEBS Letters · 2008 · 26 citations · Full text

Lipid Peroxidation, Pharmacotherapy, Experimental Pharmacology +18

Preclinical pharmacological evaluation of the fatty acid amide hydrolase inhibitor BIA 10‐2474

Maria João Bonifácio, Filipa Sousa, C. C. P. Aires et al. · British Journal of Pharmacology · 2020 · 14 citations · Full text